| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0000737 | Dna catabolic process, endonucleolytic | Increases phenotype | PMID:33392205 |
| GO:0001541 | Ovarian follicle development | Decreases phenotype | PMID:31424294 |
| GO:0001547 | Antral ovarian follicle growth | Increases phenotype | PMID:31424294 |
| GO:0004000 | Adenosine deaminase activity | Increases phenotype | PMID:39577800 |
| GO:0004112 | Cyclic-nucleotide phosphodiesterase activity | Increases phenotype | PMID:39577800 |
| GO:0004784 | Superoxide dismutase activity | Decreases phenotype | PMID:31424294 |
| GO:0006171 | Camp biosynthetic process | Increases phenotype | PMID:28858478 |
| GO:0006629 | Lipid metabolic process | Affects phenotype | PMID:31820560 |
| GO:0006701 | Progesterone biosynthetic process | Decreases phenotype | PMID:31424294 |
| GO:0006874 | Cellular calcium ion homeostasis | Affects phenotype | PMID:32508751 |
| GO:0006915 | Apoptotic process | Increases phenotype | PMID:39577800 |
| GO:0007057 | Spindle assembly involved in female meiosis i | Affects phenotype | PMID:33392205 |
| GO:0007127 | Meiosis i | Affects phenotype | PMID:33392205 |
| GO:0007283 | Spermatogenesis | Decreases phenotype | PMID:29940534 |
| GO:0008202 | Steroid metabolic process | Affects phenotype | PMID:24563381 |
| GO:0008210 | Estrogen metabolic process | Increases phenotype | PMID:24563381 |
| GO:0008283 | Cell population proliferation | Affects phenotype | PMID:24213142; PMID:24213142; PMID:28616630; PMID:37182577; PMID:39577800 |
| GO:0008284 | Positive regulation of cell population proliferation | Increases phenotype | PMID:28591870; PMID:30099086 |
| GO:0008285 | Negative regulation of cell population proliferation | Increases phenotype | PMID:29555536; PMID:32763284 |
| GO:0016042 | Lipid catabolic process | Increases phenotype | PMID:31424294 |
| GO:0016345 | Female meiotic chromosome movement towards spindle pole | Affects phenotype | PMID:33392205 |
| GO:0022402 | Cell cycle process | Affects phenotype | PMID:33940105 |
| GO:0030182 | Neuron differentiation | Decreases phenotype | PMID:39577800 |
| GO:0030283 | Testosterone dehydrogenase [nad(p)] activity | Decreases phenotype | PMID:39313105 |
| GO:0032869 | Cellular response to insulin stimulus | Affects phenotype | PMID:34186270 |
| GO:0033148 | Positive regulation of intracellular estrogen receptor signaling pathway | Increases phenotype | PMID:31388671 |
| GO:0034440 | Lipid oxidation | Increases phenotype | PMID:29940534; PMID:39577800 |
| GO:0035937 | Estrogen secretion | Affects phenotype | PMID:37182577 |
| GO:0036124 | Histone h3-k9 trimethylation | Increases phenotype | PMID:33392205 |
| GO:0036343 | Psychomotor behavior | Affects phenotype | PMID:39577800 |
| GO:0040038 | Polar body extrusion after meiotic divisions | Affects phenotype | PMID:33392205 |
| GO:0042403 | Thyroid hormone metabolic process | Affects phenotype | PMID:36881955 |
| GO:0042701 | Progesterone secretion | Affects phenotype | PMID:37182577 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:31812737; PMID:33753083 |
| GO:0044319 | Wound healing, spreading of cells | Increases phenotype | PMID:28858478 |
| GO:0045444 | Fat cell differentiation | Increases phenotype | PMID:34186270; PMID:39842701 |
| GO:0045931 | Positive regulation of mitotic cell cycle | Increases phenotype | PMID:32387340 |
| GO:0046209 | Nitric oxide metabolic process | Affects phenotype | PMID:39577800 |
| GO:0048143 | Astrocyte activation | Increases phenotype | PMID:39577800 |
| GO:0055074 | Calcium ion homeostasis | Affects phenotype | PMID:28858478 |
| GO:0061370 | Testosterone biosynthetic process | Increases phenotype | PMID:28482050; PMID:31424294; PMID:33753083; PMID:33940105; PMID:37164221 |
| GO:0071929 | Alpha-tubulin acetylation | Increases phenotype | PMID:33392205 |
| GO:0090687 | Activation of meiosis i spindle assembly checkpoint | Increases phenotype | PMID:33392205 |
| GO:0097621 | Monoamine oxidase activity | Increases phenotype | PMID:39577800 |
| GO:0098532 | Histone h3-k27 trimethylation | Increases phenotype | PMID:33392205 |
| GO:0140042 | Lipid droplet formation | Increases phenotype | PMID:32763284 |
| GO:1903046 | Meiotic cell cycle process | Affects phenotype | PMID:33392205 |
| GO:1903409 | Reactive oxygen species biosynthetic process | Increases phenotype | PMID:31424294 |
| GO:1903428 | Positive regulation of reactive oxygen species biosynthetic process | Increases phenotype | PMID:29940534 |
| GO:1903709 | Uterine gland development | Affects phenotype | PMID:36881955 |
| GO:1990138 | Neuron projection extension | Affects phenotype | PMID:31812737 |
| GO:1990375 | Baculum development | Affects phenotype | PMID:37164221 |
| GO:2000225 | Negative regulation of testosterone biosynthetic process | Increases phenotype | PMID:29940534 |
| GO:2000469 | Negative regulation of peroxidase activity | Increases phenotype | PMID:29940534 |
| GO:2000844 | Negative regulation of testosterone secretion | Increases phenotype | PMID:29940534 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.